Biomedical Innovation In The Era Of Health Care Spending Constraints
- 1 February 2015
- journal article
- Published by Health Affairs Publishing, LLC in Health Affairs
- Vol. 34 (2) , 203-209
Abstract
Insurers, hospitals, physicians, and consumers are increasingly weighing price against performance in their decisions to purchase and use new drugs, devices, and other medical technologies. This approach will tend to affect biomedical innovation adversely by reducing the revenues available for research and development. However, a more constrained funding environment may also have positive impacts. The passing era of largely cost-unconscious demand fostered the development of incremental innovations priced at premium levels. The new constrained-funding era will require medical technology firms to design their products with the features most valued by payers and patients, price them at levels justified by clinical performance, and manage distribution through organizations rather than to individual physicians. The emerging era has the potential to increase the social value of innovation by focusing industry on design, pricing, and distribution principles that are more closely aligned with the preferences—and pocketbooks—of its customers.Keywords
This publication has 13 references indexed in Scilit:
- Sofosbuvir-Based Treatment Regimens for Chronic, Genotype 1 Hepatitis C Virus Infection in U.S. Incarcerated PopulationsAnnals of Internal Medicine, 2014
- Biosimilars And The European Experience: Implications For The United StatesHealth Affairs, 2013
- Case Studies Of Orthopedic Surgery In California: The Virtues Of Care Coordination Versus SpecializationHealth Affairs, 2013
- The generic pharmaceutical industry: moving beyond incremental innovation towards re-innovationGenerics and Biosimilars Initiative Journal, 2013
- Technology Growth and Expenditure Growth in Health CareJournal of Economic Literature, 2012
- How Medicare Could Use Comparative Effectiveness Research In Deciding On New Coverage And ReimbursementHealth Affairs, 2010
- Hospital-Physician Gainsharing In CardiologyHealth Affairs, 2008
- Hospitals' Strategies for Orchestrating Selection of Physician Preference ItemsThe Milbank Quarterly, 2007
- AMCP Format Dossier Requests: Manufacturer Response and Formulary Implications for One Large Health PlanJournal of Managed Care Pharmacy, 2007
- AMCP Guidance for Submission of Clinical and Economic Evaluation Data to Support Formulary Listing in U.S. Health Plans and Pharmacy Benefits Management OrganizationsJournal of Managed Care Pharmacy, 2001